Fish oil has acquired a reputation for protecting memory that is stronger than the clinical evidence behind it. DHA is abundant in brain tissue, so the idea that taking more might preserve cognition has an understandable biological appeal. For someone with a family history of Alzheimer’s, that possibility can make a daily supplement feel like a sensible precaution.

The difficulty is that a nutrient’s importance to normal physiology does not tell us whether additional supplementation will prevent disease. A trial can help test that assumption, particularly when researchers measure both a biological response and outcomes relevant to patients.

What the DHA Trial Found

The trial enrolled 365 adults aged 55 to 80 without dementia, with low dietary DHA intake and at least one dementia risk factor. Participants received 2 grams of DHA daily or placebo for 24 months. The primary outcome was the change in the cerebrospinal fluid DHA-to-arachidonic-acid ratio at six months; cognitive and imaging measures were secondary or exploratory outcomes.¹

Supplementation increased that ratio, supporting central nervous system target engagement, without evidence that APOE ε4 status modified this primary response. Investigators found no treatment differences in cognitive performance or brain volumes over 24 months. Dropout was substantial at 38%, largely attributed to the COVID-19 pandemic, which limits interpretation.¹

Why a Better Biomarker Is Not Enough

The distinction between a biological response and a clinical benefit matters whenever a supplement is promoted using laboratory results. Demonstrating that an intervention changes a measurement is useful, but the next question is whether that change improves health, function, or disease risk.

In this case, the results do not justify describing high-dose DHA as established dementia prevention. Equally, a study of this duration and design cannot settle whether every pattern of omega-3 intake influences lifetime risk. Unanswered questions remain research questions; they should not be presented to patients as benefits that have already been demonstrated.

Other Uses of Omega-3s Require Their Own Evidence

EPA and DHA contribute to cell membranes and signaling pathways, and DHA is concentrated in the brain and retina. Adequate nutrition remains important regardless of whether supplementation improves cognition. Eating fish as part of a balanced diet is also a different intervention from taking an isolated, high-dose nutrient.²

Omega-3 treatment has uses outside dementia research. Prescription products can lower triglycerides, but cardiovascular outcomes depend on the formulation and patient population. An over-the-counter fish oil product should not be assumed equivalent to a prescription medication simply because both contain omega-3 fatty acids.²

For example, REDUCE-IT demonstrated cardiovascular benefit from prescription icosapent ethyl, an EPA-only product, in selected statin-treated patients with elevated triglycerides and cardiovascular disease or diabetes with additional risk factors. Those findings do not establish a dementia benefit or apply automatically to other omega-3 formulations.³

The HormoneSynergy® Perspective

At HormoneSynergy®, a supplement recommendation should have a defined purpose. We consider dietary intake, the medical concern being addressed, the proposed formulation and dose, and how benefit will be assessed. Measuring omega-3 status may add information in selected circumstances, but improving a blood measurement does not itself demonstrate protection against Alzheimer’s.

Cognitive health also warrants attention beyond supplementation. Blood pressure, diabetes, physical activity, sleep, hearing, mood, and medication effects may influence function and deserve appropriate evaluation. Persistent memory changes require a clinical assessment rather than an adjustment to a supplement regimen alone.⁴

We should be able to recommend an omega-3 product for an appropriate purpose while acknowledging a trial that did not show the hoped-for cognitive benefit. Patients need that distinction to understand what they are taking and what they can reasonably expect from it.

Reviewing an Existing Recommendation

Someone already taking fish oil can begin by reviewing why it was recommended. Supporting dietary intake, treating elevated triglycerides, and trying to prevent dementia are different goals. The product and dose should fit the intended purpose.

Higher doses warrant medical review. Some high-dose omega-3 trials have reported increased atrial fibrillation risk, and medication interactions should be considered, particularly with anticoagulants. This does not establish that the DHA trial itself caused those problems; it is part of assessing omega-3 treatment more broadly.²

Frequently Asked Questions

Did this trial show that DHA prevents dementia?

No. It demonstrated a change in a cerebrospinal fluid marker but found no treatment differences in cognition or measured brain volumes over two years. It did not establish long-term prevention of dementia diagnoses.

Was the dose 2 grams of fish oil?

No. Participants received 2 grams of DHA daily. Total fish oil weight and DHA content are different measurements, so they should not be used interchangeably.

Does a higher omega-3 level prove brain protection?

No. A higher level can show a biological response to intake, but it does not by itself demonstrate improved cognition or reduced Alzheimer’s risk.

Should I stop taking an omega-3 product?

Review the reason for treatment with your clinician. The relevance of this trial depends on your treatment goal, formulation, dose, and medical history. Do not change prescription omega-3 therapy without discussing it with the prescriber.

References

1. Yassine HN, et al. CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial. EBioMedicine. 2026;129:106316. doi:10.1016/j.ebiom.2026.106316. Read the trial.
2. National Institutes of Health Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals.
3. Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019;380:11–22. Read REDUCE-IT.
4. National Institute on Aging. Cognitive Health and Older Adults.

This article provides general education and does not replace individualized medical advice. Supplement and prescription recommendations should be reviewed with your treating clinician.